HUE035295T2 - A Poli(ADP-ribóz)-polimeráz (PARP) dihidro-pirido-ftalazinon inhibitorai - Google Patents

A Poli(ADP-ribóz)-polimeráz (PARP) dihidro-pirido-ftalazinon inhibitorai Download PDF

Info

Publication number
HUE035295T2
HUE035295T2 HUE14154664A HUE14154664A HUE035295T2 HU E035295 T2 HUE035295 T2 HU E035295T2 HU E14154664 A HUE14154664 A HU E14154664A HU E14154664 A HUE14154664 A HU E14154664A HU E035295 T2 HUE035295 T2 HU E035295T2
Authority
HU
Hungary
Prior art keywords
phenyl
phthalazin
dihydro
pyrido
methyl
Prior art date
Application number
HUE14154664A
Other languages
English (en)
Inventor
Bing Wang
Daniel Chu
Original Assignee
Medivation Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivation Technologies Inc filed Critical Medivation Technologies Inc
Publication of HUE035295T2 publication Critical patent/HUE035295T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)

Claims (4)

  1. A ΡΟΙί(ΑΟΡ4?ΙδΟ2ρΡΟΙΙΜΕΡΑ2 (PARR; OiHIBPO-PiPäDO-PTALAZiNöhi iNHÎBlTORAi SZABAüALMî IGÉNYPONTOK
    1. Az alábbi áitalános képlettel jeltefnezhetó vegyöleb
    vagy armek. agy -gyógyászaííísg «Ifogadhafô .sója vagy «zoiváíja, 2. A 1, igénypont szsnt dl vegyütst. áhöl a vagyülat 0; ίδΡ,θΒ’-δ'ΡίυοΓ-β-ίΑ.ήϋΟΓ^η^'θ-ίΙ-ΐΡδΙϋ’'’»/·/"'! ,2;4-t!ÍíiZo!-ö’iij'3;3-dih:<iro-2H-pifldo[4,3,2'de:ftáiazfo"3{7M"On vagy ennek agy gyégyászaslag elfogadható sója; vagy (it) {8δ!δ^}>§-Γΐυ0Γ*β'(4-?ΚϊόΗ0ΓίΙΓί'9^Ί'^©Ιί?-ί/ϊ^>2!4·-ΐ0320^δ"Η/*δ:δ':€ίί^^ΐΓ0>2ΗηρίΗ00[4ί3,2^0}^ΐ0?.ίή--3(?Η}<·οή vagy ennek agy oyégyászatiiag elfogadható sója. 3 Az 1 igénypont szénné vegyelek ahes a vegymet {aSfoR}-5-éíseí'S-í4-ánorfonii;G'Ít-n5et:ntA'1,2.naf:azoná-fo-é.ó' dihldro-2H-pindo[4,3.2-delftälaztri'3{?H}»on vagy ennek egy gyógyászatilag elfogadható sója.
  2. 4. Gyógyászati kószíanóny, amely tartalmazza az 1. Igénypont szenntk sióból általános képlettel jeliemezbető vegyöietek
    vagy ennek egy gyógyászatilag eifogsöható sósát vagy gyogyaszahfog elfogadható szolvátját, valamint agy gyógyászatilag elfogadható hordozók segédanyagok kötőanyagét vegy oidószatt ó. Á 4, igénypont szerinti gyógyászati készítmény. ahol a vegyúiet g} (0R,SS;->&amp;->é|po^844"ttóasíaniipáaj-metlk ^ló^áflszokmiiASj.őlniófö-kákóirídbjA jJ-detááiazin^tZHjfon vagy ennek egy gyógyészstííag elfogadható sója; vagy {üt 5δ5.δΑ}·-5'ΡΐοοΓ'δ-ί4ΑΙηβΓίοηΙΙ;-§-(ηηηηίΐηΐΗ.·ΐ,?,4όη5ζοΙ·'0-ίΐ)-3:2-οΙ0!θη;'?ήί-ρ!ΓΐοοΙ4,3A-deiftaiazinfotZHj-on vagy ennek egy gyógyáSzstifog elfogadható sója.
  3. 6. Az 5, Igénypont szehntí készítmény; ahol a végyüfot (§Si8R)'S-kpOi'-'8A4mppitsn||}~§AAf'iietlkW'i;2,4foiazokSdS}^.fo éfoidrô-2Hfoiridofo,3.2mejftétszfo-3{?H)fon vagy ennek égy gyègyè&amp;zatllgg elfogadható sója. ?.· A 4, vágy .§, igénypont szerinti készítmény. ahöi â; fô-szîôbêny orális,. Oskkéüs. sztíbiingváiis. intrevénès, .InhÄfos, nazáfis. fojekeiós, helyi, ezéniéexeti, rgktáíis. .parsnteíális vagy transzdermáiis bevitelre alkeimes. A 7 igénypont szerinti készítmény, ahol s készítmény eratis oevdeire aíkaimas. S. A S. igénypónt szerint; készitmeny, she; sz orális adagotásó kàszitmérty egységrfozisú gyógyszgríerme, zhei adett esetben sz ogyeégdézis egy tabletta. por, piruia, drazsé, kapszula, folyadék, gél, szirup, wir. sörö szuszperizlo vagy szeszpenzié. 10. n * igv'-gm : s?t- st \.e, ;.z ogv»,\ce. », gvegtszerte;ms »om.afoU 1 e» kotjbc , ; \ i-.'zcr mennyiséget fe;lalmaz a veoyplotbét vagy annak gyógyaszafilág elfogádhstó sójából vagy szeiváháPéi 1 1, A 8 igénypont szerinti készítmény, phot ez m-alls Pevdelro alkalmas.készítmény. jij kêruibeks 0 01 es koróibgiul 2,5mgíkg vegyulefet vagy annak gyogyaszaiilag elfogadható sóját vagy szolváíjét tertairnszó dózisban van. seri megiéíg; a beedheto napi ögzlsnak: vagy (il) kérüibeíd; δ,δ és kérüíbetöí WO mg vegyófotef vagy annak gyógyászaólsg elfogadható sóját vagy szeivéfiét tartalmazó oázisban van amit adott esetben napi fogieljebb négy adagra efosztott soztsban vagy rotate formában tenet beadm
  4. 12, Az 1-3, igénypontok bárrnelylka szerinti vágyóiét vagy a foil. igénypanfok bármelyike szerinti készítmény a rák kezeiésl médszeráben veié folhesznélásre. 13, A 12. Igénypont szerinti felhasználásé vegyiket vagy készítmény. ahoi a módszer abban áll, négy s vegysiietsi vagy a készítményt ogyldejőieg vagy egymást követben juttattak be fontsaié sugárzás, egy vagy több kemoterápiás azét vágy ezek kombinációja mellett, 14, A 12, igénypont szerinti feihasznaiasé vágyóiét vagy készítmény, ahoi a rák típusa az alábbiak közei válesztefo amforák; petefészekrák, endomelrtomdumpr, méhnyskrák, tüdőrák, prosztatarák, hasnyairnirigyrak, bemstoiéglai daganat, íeukémte, vastágbélrák, Péfoagánsk giiobiestoniá, iimfoma és melanoms iá, A 14. igénypont szerinti fefoasznáiásé: vegyetek vagy készítmény, ahoi a rak típusa az alábbiak közói választott; emlőrák, petefeszekräk, tüdőrák, prosztatarák, hashyáimirigyfák, vastagbéirák és melanoma. W. A 13, igénypont szénné feinasznaiasú vagyaiét vagy keszumony, aboi az egv vagy febb kemefompiás szer egymásfoi főggétjenói (i) áz alábbiak közei válásztott; afemfezumob, grzsnthoxid, pegiiáit aszparagloáz, nem pegiiáit aszporaginéz, bevamzumab. esfeximab, ospiaiin. eladóéin. özunotubscínfeoxorubíoínádaíobímf! mnoteoan, ffodersbin. 5-ttnonjrees, gemtuzumao, metotrexét Paciitsimbfo texoi. temczofomid. t;oguanin. egy antiosztrogen hormonanaiég. egy snt.anöfogen bormonsnaibg, egy gonadotropin'f&amp;iszabadiio hormongnafog. alfa interferon, busuilan, mssplialan, meehleretnamin, tretinoin, irínotooart, topoteoan. ggümőmb, Imaflntb, stfopttrlnel, fiigrastlm, gramseifonfondansetronfpaienosstiOnds dronsbinok vagy ίίί) egy afkiiâiàsM vagy egy topoisomaráa-l inhibitor, ahoi adott esetben ez aiklláíöszsr vagy s iopoizomeráz-·; ínhibrtöt meííí-meténszuitenát, lemozteomld. riaearbazin (OTIC). Tepoteoan, ínnotésáh, Rehíísoán, Bzeteoen. Lurjetédsn, Gáaatecsn. Diílomoiecan ítmrrmkamptoteclnek), egy ?-szubsztifeái{ nem-sllateoan, a z-sziííl-cemptothecin. BMP 1350 vsgy XR 11576/MLN XX, vagy öü) innotéeen, osspiatin vagy teozslomkt ír. A Ί2·1δ. igénypontok szerint; telhaszuáiásá vsgyülst vagy készítmény. ahoi s daganatban íiter-yes a DNS-kettösszál töréseinek sDSB- Doubte strand Break) nomcteg fek*obtoá<?óthggo |HR - Homologous Reoombinadenj javitasi útvonala 18. A,1 ?. igénypont szét inti lelhaszrsálásö vegyólet vagy készítmény. ahol a rák egy vagy több olyan rákos sejtet tartalmaz, {B amelynek a normális sejtekhez késest ősökként vagy megszűnt a képessége a ÖMS DSB HP, mechanizmus éltek kijavítására, ahoi e rákos sejtek értett esetben BRCA1- vagy 8RCA2-hiányos íenoiipussal rendelkeznek, shoi a rákos sejtek ezentéiéi adott esetben BRCA1 - vagy 3RCA2-niányeáák is: vagy (ti) amely hiányos s DNS DSB HR mscbanlzmdé általi javításában résztvevő proteinekben, ahol a rákos sejtek adott esetben hiányosak ez alábbiakban- ATM, Racist., Rsd52, RsdbA Radőö. MRE11. N8S1. XRCCX XRCC3, oASl. RPA. CtíPésMBC. 13, A12. igsnygont szerint; ieihaeználásá vegykist vagy készitmény, shot a kezeiendö stony hetsroz-göts a következőkre: 11} mteroXXS \Ηχ( ""'B t ste i -m aim >. pé k<'t\0i,e"éi v > lő gé'O' t , jl; j muteclö s SRCAl-oert éstesgy BRCA2-ben. 23. A12-18. Igénypontok szerinti telhasználásá vegyiket vagy készítmény, ahol a daganat: (i) hiányos a hibás bázíspárosodás (mismatch) DNS-javííási élvonalban, ahol adott esetben a rákos sejtek hiányosak MutS-ben, MatH-bon és MutLhem vagy (ii) a ősökként vagy károsodott BMS-jsvifö útvonalak következtében mikroszeteiirte instabilitást mutat; Vágy (Ili) a csökkent vagy károsodott DNS-javltó útvonalak következtében genornrnsíábiiitást mutât.
HUE14154664A 2008-08-06 2009-07-27 A Poli(ADP-ribóz)-polimeráz (PARP) dihidro-pirido-ftalazinon inhibitorai HUE035295T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8668708P 2008-08-06 2008-08-06
US15103609P 2009-02-09 2009-02-09
US17308809P 2009-04-27 2009-04-27

Publications (1)

Publication Number Publication Date
HUE035295T2 true HUE035295T2 (hu) 2018-05-02

Family

ID=41129519

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE14154664A HUE035295T2 (hu) 2008-08-06 2009-07-27 A Poli(ADP-ribóz)-polimeráz (PARP) dihidro-pirido-ftalazinon inhibitorai
HUS1900053C HUS1900053I1 (hu) 2008-08-06 2019-12-19 A Poli(ADP-ribóz)-polimeráz (PARP) dihidro-pirido-ftalazinon inhibitorai

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUS1900053C HUS1900053I1 (hu) 2008-08-06 2019-12-19 A Poli(ADP-ribóz)-polimeráz (PARP) dihidro-pirido-ftalazinon inhibitorai

Country Status (31)

Country Link
US (7) US8012976B2 (hu)
EP (3) EP2767537B1 (hu)
JP (3) JP5984389B2 (hu)
KR (1) KR101846029B1 (hu)
CN (3) CN104478875B (hu)
AR (1) AR072970A1 (hu)
AU (1) AU2009279944B2 (hu)
BR (1) BRPI0917119B1 (hu)
CA (1) CA2732797C (hu)
CY (3) CY1115022T1 (hu)
DK (2) DK2326650T3 (hu)
ES (2) ES2466565T3 (hu)
FR (1) FR19C1071I2 (hu)
GB (1) GB2462361A (hu)
HK (2) HK1157755A1 (hu)
HR (1) HRP20170982T1 (hu)
HU (2) HUE035295T2 (hu)
IL (1) IL211070A (hu)
LT (2) LT2767537T (hu)
LU (1) LUC00140I2 (hu)
MX (1) MX2011001328A (hu)
NL (1) NL301021I2 (hu)
NO (1) NO2019042I1 (hu)
NZ (1) NZ591166A (hu)
PL (2) PL2767537T3 (hu)
PT (2) PT2326650E (hu)
SG (2) SG193842A1 (hu)
SI (2) SI2767537T1 (hu)
TW (2) TW201422617A (hu)
WO (1) WO2010017055A2 (hu)
ZA (1) ZA201100897B (hu)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8012976B2 (en) * 2008-08-06 2011-09-06 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
CA2747252C (en) 2008-12-19 2018-09-18 Vertex Pharmaceuticals Incorporated Pyrazine derivatives useful as inhibitors of atr kinase
CN102869258A (zh) * 2010-02-03 2013-01-09 生物马林药物股份有限公司 用于pten基因缺失相关疾病的治疗的聚（adp-核糖）聚合酶（parp）的二氢吡啶并酞嗪酮抑制剂
US20110190266A1 (en) * 2010-02-04 2011-08-04 Daniel Chu 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
PT2533640T (pt) * 2010-02-08 2017-01-03 Medivation Technologies Inc Processos de síntese de derivados de di-hidropiridoftalazinona
WO2011130661A1 (en) * 2010-04-16 2011-10-20 Biomarin Pharmaceutical Inc. Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp)
CA2798763A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
TWI557123B (zh) * 2010-10-21 2016-11-11 梅迪維新技術公司 結晶型（８Ｓ，９Ｒ）－５－氟－８－（４－氟苯基）－９－（１－甲基－１Ｈ－１，２，４－三唑－５－基）－８，９－二氫－２Ｈ－吡啶并［４，３，２－ｄｅ］呔－３（７Ｈ）－酮甲苯磺酸鹽
WO2012166151A1 (en) * 2011-06-03 2012-12-06 Biomarin Pharmaceutical Inc. Use of dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) in the treatment of myelodysplastic syndrome (mds) and acute myeloid leukaemia (aml)
WO2013028495A1 (en) * 2011-08-19 2013-02-28 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma
AU2012315384B2 (en) 2011-09-30 2017-08-10 Vertex Pharmaceuticals Incorporated Treating pancreatic cancer and non-small cell lung cancer with ATR inhibitors
US9035053B2 (en) 2011-09-30 2015-05-19 Vertex Pharmaceuticals Incorporated Processes for making compounds useful as inhibitors of ATR kinase
DK2797921T3 (en) 2011-12-31 2017-10-02 Beigene Ltd FUSED TETRA- OR PENTA-CYCLIC DIHYDRODIAZEPINOCARBAZOLONES AS PARB INHIBITORS
MX2014008071A (es) * 2011-12-31 2015-07-06 Beigene Ltd Tetra o penta-piridoftalazinonas ciclicas fusionadas como inhibidores de poli(adenosin-difosfato-ribosa)polimerasas.
CN115778934A (zh) 2012-01-20 2023-03-14 德玛公司 经取代的己糖醇类用于治疗恶性肿瘤的用途
LT2833973T (lt) 2012-04-05 2018-02-12 Vertex Pharmaceuticals Incorporated Junginiai, tinkami naudoti kaip atr kinazės inhibitoriai, ir jų kombinuotas gydymas
EP2904406B1 (en) 2012-10-04 2018-03-21 Vertex Pharmaceuticals Incorporated Method for measuring atr inhibition mediated increases in dna damage
EP2918292B1 (en) 2012-11-08 2019-12-11 Nippon Kayaku Kabushiki Kaisha Polymeric compound having camptothecin compound and anti-cancer effect enhancer bound thereto, and use of same
PT2968316T (pt) 2013-03-13 2019-10-29 Forma Therapeutics Inc Derivados de 2-hidroxi-1-{4-[(4-fenilfenil)carbonil]piperazin-1-il}etano-1-ona e compostos relacionados como inibidores da sintase de ácidos gordos (fasn) para o tratamento do cancro
EP3024457A4 (en) 2013-07-26 2017-06-28 Update Pharma Inc. Compositions to improve the therapeutic benefit of bisantrene
TW201605814A (zh) * 2013-11-07 2016-02-16 拜奧馬林製藥公司 用於合成經保護之ｎ－烷基三唑甲醛的三唑中間體
CN103772395B (zh) * 2014-01-23 2016-05-11 中国药科大学 一类具有parp抑制活性的化合物、其制备方法及用途
KR102456088B1 (ko) 2014-04-04 2022-10-19 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
CA2950780C (en) 2014-06-17 2023-05-16 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of chk1 and atr inhibitors
EA201790290A1 (ru) * 2014-07-31 2017-07-31 Медивэйшн Текнолоджиз, Инк. Формерные соли (2s,3s)-метил 7-фтор-2-(4-фторфенил)-3-(1-метил-1h-1,2,4-триазол-5-ил)-4-оксо-1,2,3,4-тетрагидрохинолин-5-карбоксилата и способы их получения
WO2016138574A1 (en) 2015-03-02 2016-09-09 Sinai Health System Homologous recombination factors
WO2017003723A1 (en) 2015-07-01 2017-01-05 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
BR112018003634B1 (pt) 2015-08-25 2023-11-21 Beigene Switzerland Gmbh Forma cristalina de sesqui-hidrato de um inibidor parp, método de preparação da dita forma cristalina e composição farmacêutica compreendendo a dita forma
JP7187308B2 (ja) 2015-09-30 2022-12-12 バーテックス ファーマシューティカルズ インコーポレイテッド Ｄｎａ損傷剤とａｔｒ阻害剤との組み合わせを使用する、がんを処置するための方法
US9708319B1 (en) * 2016-06-13 2017-07-18 Yong Xu Synthesis of PARP inhibitor talazoparib
EP3519051B1 (en) 2016-09-27 2021-09-22 Beigene, Ltd. Treatment of cancers using combination comprising parp inhibitors
JP6541635B2 (ja) * 2016-10-28 2019-07-10 ベイジーン リミテッド Ｐａｒｐ阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン
CN108210461A (zh) * 2016-12-16 2018-06-29 中国科学院上海药物研究所 一种Talazoparib药物组合物及其应用
CN107573341B (zh) * 2016-12-29 2020-08-14 广州丹康医药生物有限公司 作为parp抑制剂的新型稠环化合物、其制备方法和应用
CN107556312B (zh) * 2016-12-29 2020-04-10 广州丹康医药生物有限公司 具有parp抑制活性的新型稠环化合物、其制备方法和用途
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
CN115433187B (zh) 2017-02-28 2023-10-27 百济神州(苏州)生物科技有限公司 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式组合物及其用途
WO2018205938A1 (zh) * 2017-05-08 2018-11-15 广州丹康医药生物有限公司 Parp抑制剂、其药物组合物、制备方法和应用
WO2019023278A1 (en) 2017-07-25 2019-01-31 Crinetics Pharmaceuticals, Inc. MODULATORS OF SOMATOSTATIN AND USES THEREOF
US20200254091A1 (en) 2017-10-13 2020-08-13 Merck Patent Gmbh Combination of a PARP Inhibitor and a PD-1 Axis Binding Antagonist
TW201938165A (zh) 2017-12-18 2019-10-01 美商輝瑞股份有限公司 治療癌症的方法及組合療法
CN110272419A (zh) * 2018-03-14 2019-09-24 上海艾力斯医药科技有限公司 二氢吡啶并酞嗪酮衍生物、其制备方法及应用
CN108341792B (zh) * 2018-04-28 2021-09-17 苏州莱克施德药业有限公司 一种Volasertib中间体1-环丙基甲基哌嗪的制备方法
CN108676888B (zh) * 2018-07-12 2022-01-28 吉林大学 一种肺部恶性肿瘤易感性预测试剂盒及系统
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
CN113382633A (zh) 2018-10-29 2021-09-10 福马治疗股份有限公司 (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式
WO2020095184A1 (en) 2018-11-05 2020-05-14 Pfizer Inc. Combinations for treating cancer
AU2020274113A1 (en) 2019-05-14 2021-11-11 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US20220227757A1 (en) 2019-05-14 2022-07-21 Suzhou Four Health Pharmaceuticals Co., Ltd. Quinazoline-2,4-dione derivatives as parp inhibitors
WO2021097046A1 (en) 2019-11-13 2021-05-20 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN111116514B (zh) * 2020-01-10 2024-03-19 广州科锐特生物科技有限公司 一种1-环丙甲酰基哌嗪盐酸盐的制备方法
JP2023517044A (ja) 2020-03-09 2023-04-21 ファイザー・インク 融合タンパク質およびその使用
AU2021379314A1 (en) 2020-11-13 2023-06-15 Pfizer Inc. Talazoparib soft gelatin capsule dosage form
EP4256088A1 (en) 2020-12-07 2023-10-11 Pfizer Inc. Methods of identifying a tumor that is sensitive to treatment with talazoparib and methods of treatment thereof
AU2022246058A1 (en) 2021-03-23 2023-10-05 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CA3214316A1 (en) 2021-03-24 2022-09-29 Pfizer Inc. Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer
WO2022216979A1 (en) * 2021-04-08 2022-10-13 Board Of Regents, The University Of Texas System Compounds and methods for theranostic targeting of parp activity
AU2022269568A1 (en) 2021-05-03 2023-11-16 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
EP4089093A1 (en) * 2021-05-12 2022-11-16 Eberhard Karls Universität Tübingen Medizinische Fakultät Radiosynthesis of [18f] talazoparib
WO2023131894A1 (en) 2022-01-08 2023-07-13 Pfizer Inc. Genomic loss of heterozygosity as a predictive biomarker for treatment with talazoparib and methods of treatment thereof
WO2023201338A1 (en) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
WO2023233295A1 (en) 2022-06-01 2023-12-07 Ideaya Biosciences, Inc. Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof
WO2023239789A1 (en) * 2022-06-08 2023-12-14 Valo Health, Inc. Tricyclic phthalazinone parp inhibitors and methods of use
CN115572218B (zh) * 2022-08-29 2024-04-16 江阴勒森生物科技有限公司 一种2-溴-3-羟基苯甲醛及其相关化学发光底物中间体的制备方法
WO2024074959A1 (en) 2022-10-02 2024-04-11 Pfizer Inc. Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer
CN116283924A (zh) * 2023-01-16 2023-06-23 四川效佳科技有限公司 一种药用级纯度的苯甲酸利扎曲普坦的重结晶方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US106631A (en) * 1870-08-23 Improvement in seed-planter
US4415504A (en) 1981-09-21 1983-11-15 Tanabe Seiyaku Co., Ltd. p-Hydroxyphenylglycine.α-phenylethanesulfonate, process for production thereof and utilization thereof in resolution of p-hydroxyphenylglycine
JPS58225065A (ja) 1982-06-21 1983-12-27 Nippon Shinyaku Co Ltd ２−キノロン誘導体
US5328905A (en) * 1987-07-20 1994-07-12 Duphar International Research B.V. 8,9-anellated-1,2,3,4-tetrahydro-β-carboline derivatives
MX9701075A (es) 1994-08-12 1998-03-31 Myriad Genetics Inc Mutaciones en vivo y polimorfismos en el gen de susceptibilidad al cancer de pecho y ovario enlazado con 17q.
WO1996005308A1 (en) 1994-08-12 1996-02-22 Myriad Genetics, Inc. Method for diagnosing a predisposition for breast and ovarian cancer
GB9505538D0 (en) * 1995-03-18 1995-05-03 Ciba Geigy Ag New compounds
ID19155A (id) 1996-12-13 1998-06-18 Tanabe Seiyaku Co Turunan-turunan piridin, pembuatannya dan intermediet untuk pembuatannya
DE19727410A1 (de) 1997-06-27 1999-01-07 Hoechst Schering Agrevo Gmbh 3-(5-Tetrazolylcarbonyl)-2-chinolone und diese enthaltende nutzpflanzenschützende Mittel
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
TW430656B (en) 1997-12-03 2001-04-21 Dainippon Ink & Chemicals Quinolinone derivative, method for preparing the same, and anti-allergic agent
EP1077946A1 (en) 1998-05-15 2001-02-28 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
DE19921567A1 (de) 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
JP2001302669A (ja) * 2000-04-18 2001-10-31 Meiji Seika Kaisha Ltd 三環性フタラジノン誘導体
JP2002284699A (ja) 2001-03-28 2002-10-03 Sumitomo Pharmaceut Co Ltd 視細胞変性疾患治療剤
AR036081A1 (es) 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
SE0102315D0 (sv) 2001-06-28 2001-06-28 Astrazeneca Ab Compounds
JP3843454B2 (ja) 2002-02-19 2006-11-08 小野薬品工業株式会社 縮合ピリダジン誘導体化合物およびその化合物を有効成分として含有する薬剤
EP1340819A1 (en) 2002-02-28 2003-09-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Microsatellite markers
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
EP1400244A1 (en) * 2002-09-17 2004-03-24 Warner-Lambert Company LLC New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
CA2505876A1 (en) 2002-11-12 2004-05-27 Mochida Pharmaceutical Co., Ltd. Novel parp inhibitors
CA2517629C (en) 2003-03-12 2011-07-12 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2004105700A2 (en) * 2003-05-28 2004-12-09 Guildford Pharmaceuticals, Inc. Compounds, methods and pharmaceutical compositions for inhibiting parp
EP1716125B1 (en) 2004-02-18 2013-06-19 AstraZeneca AB Tetrazole compounds and their use as metabotropic glutamate receptor antagonits
GB0612971D0 (en) 2006-06-30 2006-08-09 Angeletti P Ist Richerche Bio Therapeutic compounds
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
JP4657384B2 (ja) 2007-05-03 2011-03-23 ファイザー・リミテッド ナトリウムチャンネルモジュレーターとしての２−ピリジンカルボキサミド誘導体
JP2010536807A (ja) 2007-08-22 2010-12-02 ４エスツェー アクチェンゲゼルシャフト キネシンスピンドルタンパク質（ｅｇ５）の阻害剤としてのインドロピリジン
ES2504690T3 (es) * 2007-10-03 2014-10-08 Eisai Inc. Compuestos inhibidores de PARP, composiciones y métodos de uso
EP2247600A4 (en) 2008-02-06 2011-09-14 Biomarin Pharm Inc BENZOXAZOLEBOXYLIC ACID AMIDE AS INHIBITORS OF POLY (ADP-RIBOSE) POLYMERASE (PARP)
US8012976B2 (en) 2008-08-06 2011-09-06 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
MX2011001563A (es) 2008-08-12 2011-03-04 Boehringer Ingelheim Int Procedimiento para la preparacion de compuestos de piperazina sustituidos con cloalquilo.
CN102869258A (zh) 2010-02-03 2013-01-09 生物马林药物股份有限公司 用于pten基因缺失相关疾病的治疗的聚（adp-核糖）聚合酶（parp）的二氢吡啶并酞嗪酮抑制剂
US20110190266A1 (en) 2010-02-04 2011-08-04 Daniel Chu 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)
PT2533640T (pt) 2010-02-08 2017-01-03 Medivation Technologies Inc Processos de síntese de derivados de di-hidropiridoftalazinona
WO2011130661A1 (en) 2010-04-16 2011-10-20 Biomarin Pharmaceutical Inc. Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp)
WO2011140009A1 (en) 2010-05-04 2011-11-10 Biomarin Pharmaceutical Inc. Methods of using semi-synthetic glycopeptides as antibacterial agents
TWI557123B (zh) 2010-10-21 2016-11-11 梅迪維新技術公司 結晶型（８Ｓ，９Ｒ）－５－氟－８－（４－氟苯基）－９－（１－甲基－１Ｈ－１，２，４－三唑－５－基）－８，９－二氫－２Ｈ－吡啶并［４，３，２－ｄｅ］呔－３（７Ｈ）－酮甲苯磺酸鹽
WO2012166151A1 (en) 2011-06-03 2012-12-06 Biomarin Pharmaceutical Inc. Use of dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) in the treatment of myelodysplastic syndrome (mds) and acute myeloid leukaemia (aml)
WO2013028495A1 (en) 2011-08-19 2013-02-28 Biomarin Pharmaceutical Inc. Dihydropyridophthalazinone inhibitors of poly (adp-ribose) polymerase (parp) for the treatment of multiple myeloma
US20130053365A1 (en) 2011-08-30 2013-02-28 Biomarin Pharmaceutical, Inc. Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
TW201605814A (zh) 2013-11-07 2016-02-16 拜奧馬林製藥公司 用於合成經保護之ｎ－烷基三唑甲醛的三唑中間體
EA201790290A1 (ru) 2014-07-31 2017-07-31 Медивэйшн Текнолоджиз, Инк. Формерные соли (2s,3s)-метил 7-фтор-2-(4-фторфенил)-3-(1-метил-1h-1,2,4-триазол-5-ил)-4-оксо-1,2,3,4-тетрагидрохинолин-5-карбоксилата и способы их получения

Also Published As

Publication number Publication date
PL2767537T3 (pl) 2017-09-29
CY1115022T1 (el) 2016-12-14
US20210069191A1 (en) 2021-03-11
GB2462361A (en) 2010-02-10
LTC2767537I2 (lt) 2020-11-10
HK1157755A1 (en) 2012-07-06
BRPI0917119A2 (pt) 2015-11-17
CN102171214A (zh) 2011-08-31
RU2514937C2 (ru) 2014-05-10
NZ591166A (en) 2012-11-30
TWI448464B (zh) 2014-08-11
EP2326650B1 (en) 2014-02-26
EP2326650A2 (en) 2011-06-01
JP2018012698A (ja) 2018-01-25
WO2010017055A3 (en) 2010-05-27
PL2326650T3 (pl) 2014-07-31
ES2625817T3 (es) 2017-07-20
CY2019044I1 (el) 2020-05-29
CY1119218T1 (el) 2018-02-14
CA2732797A1 (en) 2010-02-11
US8012976B2 (en) 2011-09-06
AR072970A1 (es) 2010-10-06
PT2767537T (pt) 2017-07-17
SI2326650T1 (sl) 2014-04-30
WO2010017055A2 (en) 2010-02-11
CN103896942A (zh) 2014-07-02
EP2326650A4 (en) 2012-03-21
CA2732797C (en) 2017-01-03
US20100035883A1 (en) 2010-02-11
IL211070A0 (en) 2011-04-28
PT2326650E (pt) 2014-05-06
LUC00140I2 (hu) 2021-02-12
EP2326650B9 (en) 2014-09-10
JP2015157843A (ja) 2015-09-03
NL301021I1 (nl) 2019-12-18
SI2767537T1 (sl) 2017-08-31
AU2009279944B2 (en) 2014-09-11
US8420650B2 (en) 2013-04-16
US10780088B2 (en) 2020-09-22
FR19C1071I1 (hu) 2020-01-17
JP5984389B2 (ja) 2016-09-06
DK2767537T3 (da) 2017-06-19
LTPA2019522I1 (lt) 2019-12-27
AU2009279944A1 (en) 2010-02-11
HK1200813A1 (en) 2015-08-14
SG10201809895YA (en) 2018-12-28
CY2019044I2 (el) 2024-02-16
US11364241B2 (en) 2022-06-21
EP3241832A1 (en) 2017-11-08
FR19C1071I2 (fr) 2020-10-16
US10543209B2 (en) 2020-01-28
IL211070A (en) 2014-11-30
JP2011530513A (ja) 2011-12-22
EP2767537B1 (en) 2017-04-12
US20110237581A1 (en) 2011-09-29
NL301021I2 (nl) 2020-04-14
ZA201100897B (en) 2012-06-27
US8999987B2 (en) 2015-04-07
HUS1900053I1 (hu) 2020-02-28
RU2011108493A (ru) 2012-09-20
GB0913474D0 (en) 2009-09-16
SG193842A1 (en) 2013-10-30
LT2767537T (lt) 2017-08-10
KR101846029B1 (ko) 2018-04-06
KR20110040973A (ko) 2011-04-20
CN102171214B (zh) 2015-06-24
NO2019042I1 (no) 2019-11-28
TW201422617A (zh) 2014-06-16
DK2326650T3 (en) 2014-03-10
US20180117045A1 (en) 2018-05-03
CN104478875B (zh) 2017-04-12
MX2011001328A (es) 2011-04-04
ES2466565T3 (es) 2014-06-10
CN104478875A (zh) 2015-04-01
US9820985B2 (en) 2017-11-21
BRPI0917119B1 (pt) 2021-07-13
LUC00140I1 (hu) 2019-12-13
EP2767537A1 (en) 2014-08-20
US20150209357A1 (en) 2015-07-30
HRP20170982T1 (hr) 2017-09-22
TW201018688A (en) 2010-05-16
US20200261454A1 (en) 2020-08-20
US20130190306A1 (en) 2013-07-25

Similar Documents

Publication Publication Date Title
US11364241B2 (en) Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
AU2018206826A1 (en) Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency
WO2011130661A1 (en) Methods of using dihydropyridophthalazinone inhibitors of poly (adp-ribose)polymerase (parp)
US20090062268A1 (en) Novel inhibitors of poly(adp-ribose)polymerase (parp)
US20130053365A1 (en) Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
US20110190266A1 (en) 5,6,6a,7,8,9-HEXAHYDRO-2H-PYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)